FDA clears 'cuffless' blood pressure tracking smartwatch from Biobeat

FDA
The company said its products are designed for long-term use in hospitals, clinics and the home. (Andrew Harnik, Associated Press)

Biobeat has received clearance from the FDA for its smartwatch-based patient monitoring device, designed to track a user’s blood pressure and other vital signs without the use of the traditional inflated cuff.

Given the OK alongside a similar 10-day patch worn on the upper torso, the devices’ optical sensors employ light to noninvasively measure changes in the skin, including pulse rate and oxygenation comparable to other devices.

The company said its products are designed for long-term use in hospitals, clinics and the home. Compared to the watch, the patch also includes a single-lead ECG.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.
Biobeat's watch and patch. (Image: Biobeat)

"This clearance opens tremendous opportunities for remote monitoring of vital signs of patients and we are excited that we can now also offer this in the U.S. market," Biobeat founder and CEO Arik Ben Ishay said in a statement. The Tel Aviv-based Biobeat's has previously received CE marks and approvals in Europe and Israel.

The products can upload their data to a cloud-based server via the person’s smartphone or through dedicated hardware within the clinic, the company said.

"Remote monitoring of patient's vital sign requires completely different technological approaches than current practice," said Chief Medical Officer Arik Eisenkraft.

"While blood pressure, heart rate and oxygenation are the backbones of monitoring, we will continue to work with the FDA to approve additional parameters for our devices," Eisenkraft said, which may include measurements of cardiac output, respiratory rate and sweat levels according to Biobeat.

Suggested Articles

A new Harvard spinout, i2O Therapeutics, hopes to have people with diabetes reach for a bottle of pills, instead of the syringe.

The U.S. federal government has tapped Philips and GM to manufacture hospital ventilators for critical COVID-19 care.

Takeda and CSL Behring have set up an alliance work on an unbranded treatment made from the plasma of patients who have recovered from COVID-19.